



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9989)**

**ANNOUNCEMENT**

**PROPOSED ISSUANCE OF CORPORATE BONDS  
AND  
CHANGE IN USE OF PROCEEDS**

**PROPOSED ISSUANCE OF CORPORATE BONDS**

On 30<sup>th</sup> March 2022, the Board (the "Board") of the Company (the "Company") (the "Proposed Issuance" of Corporate Bonds) (the "PRC") (the "EGM")

**1. ISSUE SIZE**

The Company has issued B1,000,000,000 (RMB1,000,000,000)

**2. TARGET SUBSCRIBERS**

The Board of Directors of the Company has approved the following:

**3. TERM**

The Board of Directors of the Company has approved the following term (to be inserted in the prospectus):

**4. USE OF PROCEEDS**

The Board of Directors of the Company has approved the following use of proceeds (Proceeds) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following use of proceeds (Proceeds) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following use of proceeds (Proceeds) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following use of proceeds (Proceeds) to be inserted in the prospectus:

**5. INTEREST RATE**

The Board of Directors of the Company has approved the following interest rate to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following interest rate to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following interest rate to be inserted in the prospectus:

**6. VALIDITY OF THE RESOLUTION(S)**

The Board of Directors of the Company has approved the following resolution(s) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following resolution(s) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following resolution(s) to be inserted in the prospectus:

The Board of Directors of the Company has approved the following resolution(s) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following resolution(s) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following resolution(s) to be inserted in the prospectus:

**Reasons and benefits of the Proposed Issuance**

The Board of Directors of the Company has approved the following reasons and benefits of the proposed issuance to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following reasons and benefits of the proposed issuance to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following reasons and benefits of the proposed issuance to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following reasons and benefits of the proposed issuance to be inserted in the prospectus:

# PROPOSED CHANGE IN USE OF PROCEEDS

## Use of Proceeds

Document	Year	Amount (in thousands)	Percentage
Prospectus	2020	B3,538.4	
(Net Proceeds)	2020	B3,538.4	
(Global Offering)	2020		
Interim Report	2022		30%
	2022		30%
A		B1,061.5	30%
		B1,061.5	30%
		B707.7	20%
		B707.7	20%
A	2022	B1,115.2	
	2022		
		B2,423.2	

## Proposed Change in Use of Proceeds

本公司此次發行人民幣定向增發融資總額為人民幣3,538.4百萬元，扣除發行費用後，淨募集資金為人民幣3,538.4百萬元。本公司將根據實際業務需要，對上述淨募集資金進行分配。B. 擬議用途的變更如下：

(Proposed Change in Use of Proceeds)

Business objectives	Original planned use of the Net Proceeds as disclosed in the Prospects (RMB million)	Utilised as at the date of this announcement (RMB million)	Remaining proceeds as at the date of this announcement (RMB million)	Revised allocation of unutilised Net Proceeds (RMB million)	Expected date of full utilisation of the unutilised Net Proceeds
(1) 用於支付2020年12月31日到期應付的銀行借款利息	1,061.5 (30% of the net proceeds)	1,034.4	27.1		
(2) 用於支付2020年12月31日到期應付的銀行借款利息	1,061.5 (30% of the net proceeds)		1,061.5	636.9	24 months
(3) 用於支付2020年12月31日到期應付的銀行借款利息	707.7 (20% of the net proceeds)		707.7	451.8	24 months
(4) 用於支付2020年12月31日到期應付的銀行借款利息	707.7 (20% of the net proceeds)	80.8	626.9	376.2	24 months
(5) 用於支付2020年12月31日到期應付的銀行借款利息				958.3	24 months
TOTAL:	<u>3,538.4</u>	<u>1,115.2</u>	<u>2,423.2</u>	<u>2,423.2</u>	

## Reasons for and benefits of the Proposed Change in Use of Proceeds

The proposed change in use of proceeds is a result of the COVID-19 pandemic. The company has experienced a significant decline in revenue and has incurred substantial losses. The company is currently in a state of financial distress and is unable to meet its obligations. The proposed change in use of proceeds is necessary to ensure the company's survival and to allow it to continue to operate. The company is currently in a state of financial distress and is unable to meet its obligations. The proposed change in use of proceeds is necessary to ensure the company's survival and to allow it to continue to operate.

The proposed change in use of proceeds is necessary to ensure the company's survival and to allow it to continue to operate. The company is currently in a state of financial distress and is unable to meet its obligations. The proposed change in use of proceeds is necessary to ensure the company's survival and to allow it to continue to operate. The company is currently in a state of financial distress and is unable to meet its obligations. The proposed change in use of proceeds is necessary to ensure the company's survival and to allow it to continue to operate.

B... B... 24... A... B376.2

2021 2022 2022 31

A

A

T B

B B  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

30 2022

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*

*\* for identification purposes only*